Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arfaat Khan

Cardiovascular Disease Detroit, MI Medical Doctor

NPI 1538379144 CMS profile 160398

2799 W Grand Blvd, Detroit, MI 48202

Open in the dashboard

General payments

$29,807

425 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$110,121 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Arfaat Khan of Detroit, MI is reported in the CMS Open Payments database as having received $29,807 across 425 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $110,121 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,558 65
2024 General $3,798 68
2023 General $3,242 51
2022 General $7,078 72
2021 General $2,247 62
2020 General $1,874 48
2019 General $3,010 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arfaat Khan
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Arfaat Khan were reported at $8,558. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Arfaat Khan Cardiovascular Disease median Middle half National median
2019 $3,010 $450 $127–$1,392 $163
2020 $1,874 $242 $77–$751 $114
2021 $2,247 $335 $101–$1,037 $132
2022 $7,078 $395 $121–$1,211 $149
2023 $3,242 $443 $136–$1,283 $160
2024 $3,798 $450 $136–$1,323 $164
2025 $8,558 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biosense Webster, Inc. $8,229 69 payments
  2. Abbott Laboratories $5,613 47 payments
  3. Medtronic, Inc. $5,508 145 payments
  4. Medtronic Vascular, Inc. $3,986 93 payments
  5. Boston Scientific Corporation $3,046 33 payments
  6. Medical Device Business Services, Inc. $1,097 2 payments
  7. Biotronik Inc. $415 5 payments
  8. Philips Electronics North America Corporation $298 4 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $291 6 payments
  10. Janssen Pharmaceuticals, Inc $235 3 payments
  11. Other $1,088 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,223 358 payments
  2. Travel and Lodging $12,389 65 payments
  3. Consulting Fee $4,125 1 payment
  4. Education $70 1 payment
Products named General payments · program years 2019–2025
  1. Carto 3 $3,913 63 payments
  2. Micra Pacemakers $1,855 40 payments
  3. General - Therapies $1,586 5 payments
  4. MICRA Pacemakers $1,461 23 payments
  5. Arctic Front $1,458 8 payments
  6. AVEIR Structural Heart $1,248 8 payments
  7. AVEIR Cardiac Rhythm Management $1,010 7 payments
  8. AVEIR Cardiac Rhythm Management $997 6 payments
  9. COBALT DR MRI SURESCAN $821 35 payments
  10. AMPLATZER Occluders $768 9 payments
  11. Other $7,940 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

470

Median for Hospitalist: 109

Drug cost

$181,953

Median for Hospitalist: $6,399

Branded share of claims

42.8%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 141 $169,972
Flecainide Acetate Generic 55 $3,228
Dofetilide Generic 20 $2,949
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 32 $1,927
Metoprolol Succinate Generic 50 $1,531
Amiodarone Hcl Generic 52 $1,324
Sotalol Sotalol Hcl Brand 28 $370
Metoprolol Tartrate Generic 22 $174
Warfarin Sodium Generic 13 $146
Amlodipine Besylate Generic 15 $128

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$103,525

Medicare's payments for the services billed

Medicare patients

519

Average age 75

Services billed

1,281

258 women, 261 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 64%
Heart failure 58%
Ischemic heart disease 57%
Diabetes 49%
Arthritis 47%
Chronic kidney disease 43%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
CLEVIPREX
  • CHIESI USA, INC. $9
$9 — —
KENGREAL
  • CHIESI USA, INC. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

425 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record